eGFR-C started recruiting in 2014, and the recruitment period lasted for 35 months, finishing in January 2017. 1229 patients were recruited into the main study. Another 20 joined a side-study based in Canterbury. Each patient is followed up every six months for three years. Once the last patient has had their three year follow up visit, there will be a 6 month period of data analysis and report writing before the study results are published.
The eGFR-C Chief Investigator is Dr Edmund Lamb, based at Kent and Canterbury Hospital.
The eGFR-C study is being co-ordinated by Birmingham Clinical Trials Unit, and is co-sponsored by the University of Birmingham and East Kent Hospitals University NHS Foundation Trust.
The study has been funded by the National Institute for Health Research Health Technology Assessment programme (NIHR HTA Ref: 11/103/01).
All research in the NHS is looked at by an independent group of people called a Research Ethics Committee (REC) to protect your safety, rights, wellbeing and dignity. This study has been reviewed and approved on 9th October 2013 by South East Coast - Surrey REC (Reference No: 13/LO/1349). RECs include healthcare professionals as well as non-medical people, and are completely independent from anyone organising the study.